Πλοήγηση ανά Συγγραφέα "Lytras, T."
-
Article
Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis—what is best in class? Authors’ reply
Bonovas, S.; Lytras, T.; Nikolopoulos, G.; Peyrin‐Biroulet, L.; Danese, S. (2018)Linked Content This article is linked to Bonovas et al and Tsai papers. To view these articles visit https://doi.org/10.1111/apt.14449 and https://doi.org/10.1111/apt.14480.
-
Article
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis
Bonovas, S.; Lytras, T.; Nikolopoulos, Georgios K.; Peyrin‐Biroulet, L.; Danese, S. (2018)Background Biological therapies have improved the care of patients with ulcerative colitis (UC). Tofacitinib, an oral small-molecule Janus kinase inhibitor, is potentially a new treatment option. Aim To comparatively assess ...